Gene: GRID2

2895
GluD2|SCAR18
glutamate ionotropic receptor delta type subunit 2
protein-coding
4q22.1-q22.2
Ensembl:ENSG00000152208 MIM:602368 Vega:OTTHUMG00000130975 UniprotKB:O43424
NG_034113.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.173e-1 (AD)  8.073e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LUZP20.708
PGAP10.704
KLHL130.699
SCN9A0.692
TENM10.688
CXorf570.685
PCDH170.652
ROBO10.65
NLGN10.649
KLHL10.642

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TNFRSF4-0.294
OR4F5-0.277
PLA2G5-0.264
LBP-0.26
OTX1-0.245
CXCL1-0.243
SLC25A47-0.241
GLI1-0.241
ADAMTSL5-0.239
OR4F29-0.237

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00142Glutamic AcidSmall Molecule56-86-0Approved|NutraceuticalTarget
ID Drug Name Action PubMed
D001151ArsenicArsenic affects the methylation of GRID2 gene25304211
C006632arsenic trioxidearsenic trioxide results in decreased expression of GRID2 mRNA24831965
C006780bisphenol Abisphenol A results in decreased expression of GRID2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of GRID2 gene28505145
D002110Caffeine"[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA"20230807
D002110Caffeine"Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]"20230807
C054133casticincasticin results in decreased expression of GRID2 mRNA27862857
D004390ChlorpyrifosChlorpyrifos affects the expression of GRID2 mRNA19440498
D003300Copper[Copper co-treated with Dietary Sucrose] results in increased expression of GRID2 mRNA26033743
D003300CopperCopper deficiency results in increased expression of GRID2 mRNA26033743
D003471CuprizoneCuprizone results in increased expression of GRID2 mRNA26577399
D013759DronabinolDronabinol results in decreased expression of GRID2 mRNA17578508
D019422Dietary Sucrose[Copper co-treated with Dietary Sucrose] results in increased expression of GRID2 mRNA26033743
D019422Dietary SucroseDietary Sucrose results in increased expression of GRID2 mRNA26033743
D0198131,2-Dimethylhydrazine"[APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in decreased expression of GRID2 mRNA"27840820
D000431EthanolEthanol results in decreased expression of GRID2 mRNA20655511
D000431Ethanol"N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid inhibits the reaction [Ethanol results in decreased expression of GRID2 mRNA]"20655511
D005038EthylnitrosoureaEthylnitrosourea results in increased mutagenesis of GRID2 gene16724327
D007854LeadLead affects the expression of GRID2 mRNA28903495
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of GRID2 mRNA23103053
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA"20230807
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA"20230807
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]"20230807
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GRID2 mRNA"20230807
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA"20230807
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]"20230807
D009538Nicotine"[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GRID2 mRNA"20230807
D009538Nicotine"[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA"20230807
D009538Nicotine"Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]"20230807
C520612N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid"N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid inhibits the reaction [Ethanol results in decreased expression of GRID2 mRNA]"20655511
C043680ptaquilosideptaquiloside results in decreased expression of GRID2 mRNA23274088
C501413tesaglitazartesaglitazar results in increased expression of GRID2 mRNA21515302

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004970ionotropic glutamate receptor activity-IEA-  
GO:0005234extracellularly glutamate-gated ion channel activity-IEA-  
GO:0005515protein binding-IPI12589829  27418511  
GO:0008066glutamate receptor activity-IBA21873635  
GO:0008066glutamate receptor activity-TAS9465309  
GO:0030165PDZ domain binding-ISS-  
GO:0097110scaffold protein binding-ISS-  
GO:1904315transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0007157heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules-ISS-  
GO:0007215glutamate receptor signaling pathway-TAS9465309  
GO:0010975regulation of neuron projection development-IEA-  
GO:0021707cerebellar granule cell differentiation-ISS-  
GO:0034220ion transmembrane transport-IEA-  
GO:0034613cellular protein localization-ISS-  
GO:0035235ionotropic glutamate receptor signaling pathway-IEA-  
GO:0035249synaptic transmission, glutamatergic-IBA21873635  
GO:0035249synaptic transmission, glutamatergic-ISS-  
GO:0043523regulation of neuron apoptotic process-ISS-  
GO:0050804modulation of chemical synaptic transmission-IBA21873635  
GO:0051965positive regulation of synapse assembly-IMP27418511  
GO:0060079excitatory postsynaptic potential-ISS-  
GO:0060134prepulse inhibition-ISS-  
GO:1900454positive regulation of long term synaptic depression-IMP27418511  
GO:1904861excitatory synapse assembly-IMP27418511  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-ISS-  
GO:0005887integral component of plasma membrane-TAS9465309  
GO:0008328ionotropic glutamate receptor complex-ISS-  
GO:0030054cell junction-IEA-  
GO:0043197dendritic spine-ISS-  
GO:0045202synapse-ISS-  
GO:0045211postsynaptic membrane-IBA21873635  
GO:0045211postsynaptic membrane-IEA-  
GO:0098839postsynaptic density membrane-IBA21873635  
KEGG ID KEGG Term
hsa04080Neuroactive ligand-receptor interaction
hsa04730Long-term depression
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23512105Confirming genes influencing risk to cleft lip with/without cleft palate in a case-parent trio study. (2013 Jul)Beaty THHum Genet
27355804SNPs in NRXN1 and CHRNA5 are associated to smoking and regulation of GABAergic and glutamatergic pathways. (2016 Jul)Perez-Rubio GPharmacogenomics